Monoclonal antibodies were raised against the gag proteins of a British isolate of the human immunodeficiency virus (HIV), CBL-1. Seven of the monoclonal antibodies recognized HIV gag-coded proteins of 55000 mol. wt. (p55) and 24000 tool. wt. (p24), three recognized p55/p 18 and three p 18 alone. Cross-competition assays suggested that at least two independent epitopes exist on the p24 cleaved from the p55 precursor, whereas a cluster of closely related epitopes was recognized by the p55/p18 and p18 antibodies. The panel of monoclonal antibodies was then used to compare by immunofluoresence the expression of gag-encoded antigenic determinants on HIV isolates from different geographical locations. Minor changes in epitope expression were observed in isolates from the U.S.A. and Haiti with the most notable changes being detected in isolates from Zaire, Tanzania and Uganda.
INTRODUCTION
The human immunodeficiency virus (HIV) is the aetiological agent of acquired immune deficiency syndrome and persistent generalized lymphadenopathy (Barre-Sinoussi et al., 1983; Gallo et al., 1984; Pinching & Weiss, 1986) . HIV-specific antibodies have been detected in infected patients and in those at risk of infection, using a variety of solid-phase assays including radioimmunoassays and ELISA and their presence is taken as an indication of previous exposure to the virus.
The entire genome of the HIV has been sequenced (Ratner et al., 1985; Sanchez-Pescador et al., 1985; Wain-Hobson et al., 1985) , and several proteins are encoded by the env and gag genes. The major core proteins synthesized by the gag gene have been identified by numerous workers (Montagnier et al., 1984; Safai et al., 1984; Sarngadharan et al., 1984; Schupbach et al,, 1984; Ratner et al., 1985; Robey et al., 1985) . A polypeptide of tool. wt. 55 000 (p55) is considered to be the precursor protein coded for by the gag gene Montagnier, 1985; Rather et al., 1985) . When this is processed by a protease encoded for by thepol gene, a major protein of 24000 tool. wt. (p24) and, variously, proteins of 18000 (p18) or 13000 (p13) mol. wt. are produced. None of these proteins is glycosylated and p24 and p18 are detectable both in disrupted virus-infected cells and extracellular virus, in contrast to the p55 which is detected in infected cells but present only in limited amounts in the virus .
Glycosylated proteins of the HIV env gene are considered to have tool. wt. of 160 000 (gp160), 120000 (gpl20) and 41000 (gp41). The gpl60 is processed to the external gpl20 and the transmembrane protein of 41000 tool. wt. Robey et al., 1985) .
In order to generate monospecific antibody reagents to HIV antigens, a British isolate of the virus, CBL-1 (Weiss et al., 1985) , was inoculated into BALB/c mice. Monoclonal antibodies againstgag proteins from this isolate were produced and characterized and we show how a panel of such antibodies differentiates between HIV isolates from disparate geographical origins.
METHODS
Immunization protocols. Female BALB/c mice were injected subcutaneously in the neck with an inactivated extract of HIV isolate CBL-1, in complete Freund's adjuvant. CEM/CBL-1 antigen was prepared by freezing and thawing a pellet of infected cells in phosphate-buffered saline containing 0.1 ~ Tween 20. The cell pellet and the final extract were both inactivated with 0.25~ p-propiolactone for 2 h at 4 °C.
Two further immunizations with this antigen in phosphate buffer (PB) were given intraperitoneally approximately 1 month apart with a final tail-vein boost of the isolate being given 1 month later. Fusion of the mouse spleen cells to JK Ag8.653 myeloma cells using 50 ~ polyethylene glycol was carried out 3 days later and the products were plated out into 96-well plates containing mouse peritoneal exudate cells using protocols previously described (Tedder et aL, 1982) .
Screening ofhybridomas. The supernatant fluid (SNF) from the cultures was screened for anti-HIV activity in a reverse capture ELISA. Sheep anti-mouse IgG (anti-H + L, ICN Biomedicals Ltd), was coated onto solid-phase polystyrene microwells (Nunc) and SNF from the cultures was added at a 1:4 dilution in 0-02 M-Tris-HCI pH 7.6 containing 0' 1 ~ sodium azide and 0.2 ~ bovine serum albumin for 4 h at room temperature (RT). Binding of anti-HIV IgG to the anti-mouse globulin was detected by addition of CEM/CBL-1 antigen preparation (left overnight at RT) and then peroxidase-labelled anti-HIV (polyclonal serum). After 1 h incubation at 45 °C the wells were carefully washed and the substrate, tetramethylbenzidine (TMB) in citrate/hydrogen peroxide buffer, was added. The reaction was stopped 20 min later with 2 M-H2SO , and the A,s o measured with a Titertek Multiskan recorder. Wells that gave A,5 o values of twice the negative control values were considered to react with the CEM/CBL-1 antigen preparation.
Hybridomas were also screened by indirect fixed cell immunofluorescence (IF) using an anti-mouse immunoglobulin-rhodamine conjugate (Dako Ltd, High Wycomhe, U.K,). Both CBL-l-infected CEM cells and uninfected cells were separately dried onto wells in microscope slides and then fixed with acetone. Undiluted SNF from the hybridomas was added for 40 min at RT. After washing in PB, an appropriate dilution of conjugate in PB was added and 20 min later the conjugate was washed off and the slides were mounted with coverslips. Fluorescence was considered specific if detected only in the infected cell wells.
Several hybridomas reactive by either capture ELISA or IF were cloned by limiting dilution (Tedder et al., 1982) . The clones were then expanded and injected into pristane (Aldrich)-primed BALB/c mice at a concentration of 1 × 107 cells/mouse. Ascitic fluid was harvested approximately 10 days later.
Neutralization. Neutralizing activity of HIV infectivity was assayed by inhibition of syncytium induction . Cell-free virus (104 infectious units) was incubated with SNF and the virus-SNF mixture added to C8166 cells in culture. The formation of visible syncytia was assessed numerically after 2 to 3 days in culture, and sera or SNF that gave a significant reduction in numbers were considered to contain neutralizing antibody.
Characterization of monoclonal antibodies. Antibodies in SNF from selected clones were subclassed by immunodiffusion using a Serotec Mouse Monoclonal Typing Kit (Serotec Ltd, Blackthorn, UK.). Ascitic fluids were analysed by serum protein electrophoresis (SPE; Beckman) for the presence of a monoclonal protein band. IgG was purified from the ascitic fluid by ion exchange chromatography of the fluid on DE52 (Whatman; Tedder et al., 1982) and then radiolabelled with ~25I using iodogen (Warriner Pierce Ltd, Chester, U.K.) to a specific activity of 30 gg protein per mCi (Salacinski et al., 1979) .
Immunoblotting, using the Bio-Rad anti-HIV Western Blot kit, was performed on the SNF from the hybridomas. Three ml of SNF was incubated with the nitrocellulose strips which were then washed after 30 min. Anti-mouse Ig-alkaline phosphatase conjugate (Dako) was then added at a 1 : 1000 dilution in buffer and left for a further 30 min at RT. After further washings, 3 ml of the substrate was added. The strips were then washed twice for 5 min with water and air dried.
Cross-competition assays were conducted as follows. CEM/CBL-1 antigen was fixed to a solid phase in the form of Removawells (Dynatech Ltd, Billingshurst, U.K.) which had previously been coated with human polyclonal anti-HIV IgG. 125I-labelled monoclonal antibodies and unlabelled monoclonal IgG at a 500-fold molar excess were then allowed to compete with each other for the binding sites on the HIV antigen. Significant levels of inhibition of label binding obtained between the different clones was taken to represent similarity of antigenic determinants recognized.
Typing of isolates by IF. Indirect IF was carried out on nine different isolates of HIV using infected, acetonefixed cells. SNF from the monoclonal antibodies and polyclonal human anti-HIV sera were used to examine for HIV antigen expression. Murine antibodies bound to virus were detected with anti-mouse IgG rhodamine stain as before and the human antibodies by fluorescein-conjugated anti-human IgG (Dako). When similar proportions of cells reacted with monoclonal antibody and polyclonal antibody, the fluorescent reaction was scored as positive. When the fluorescent reaction with monoclonal antibody was absent or greatly reduced in intensity, the reaction was scored as negative.
RESULTS

Identification of anti-HIV monoclonal antibodies
From the separate fusions of three mouse spleens, 1500 wells containing hybridoma cells were generated. Initial screening by capture ELISA and IF resulted in the identification of approximately 100 hybridomas. Some were reactive both by IF and capture ELISA, and others either by IF or capture alone. A selection of 30 were taken for cloning by limiting dilution. No hybridomas were identified that were able to neutralize the virus as either SNF from hybridoma screening or SNFs from clones.
Fourteen reactive hybridomas that had been successfully cloned and gave good yields of antibody in ascites (strong clonal band in SPE) were selected for further characterization (Table  l) . One hybridoma, 6D1, reacted with CEM cellular material (as determined by IF), another (DF9C3) was reactive in the capture ELISA only and two others (EB1A9, 1ESG2) were reactive in IF only. The remaining ten reacted in both IF and the capture ELISA. Ten of the hybridomas were found to secrete antibodies of the IgG 1 subclass, three secreted IgG2a, one IgG2b and another IgM (Table 1) .
Characterization of the monoclonal antibodies
Western blotting of SNF from the 13 clones that were considered virus-specific revealed that antibodies reacted variously with the products of the virus (Fig. 1) . Seven of these clones reacted with p55 and p24, three with p55, p18 and three with p18 alone.
To simplify the cross-competition results, Table 2 was constructed so that all the clones recognizing p55/p24 were together and those recognizing p55/p18 were in a group next to the p18 clones. The results suggested that 3D3 was the most broadly reactive of all the antibodies. EH12E1 and CD12B4 both appeared to recognize independent epitopes on the antigen even though they both reacted with p55 and p24 in Western blotting. CH9B2, 4H2B1, 11H9, 1D9, 4C9 and 9G5, all reactive against p18, recognized essentially the same epitope. 1D8F6, EB1A9, 1E8G2 and 9G5 labelled only poorly and showed less than 75 ~ homologous inhibition; as a result, interpretation of cross-competition results in these experiments was difficult.
Typing of isolates by IF
The proportion of cells expressing HIV antigens was variable. Thus it was necessary to compare the SNF reactivity with that given by human anti-HIV. The reactivity of gag products on various isolates of HIV was examined (Table 3a and Table 3 . DISCUSSION Hybridomas secreting monoclonal antibody to HIV were obtained by immunizing BALB/c mice with a crude lysate of CEM/CBL-l-infected cells. These antibodies have been characterized as anti-gag. The failure to produce anti-env specificity could have been the result of loss of envelope from the antigen preparation. Virus-infected cells were inactivated with flpropiolactone and disrupted by procedures which may have destroyed the envelope antigens of the virus. However this antigen preparation proved quite adequate for raising monoclonal antibodies against HIV gag proteins. Our failure to raise anti-env is unlikely to be the result of the screening method since the anti-HIV-peroxidase conjugate used in the capture assay could detect envelope proteins. This was demonstrated by the binding of the conjugate to recombinant env products captured on an anti-HIV-coated solid phase (results not shown).
Cross-competition results
Detection of HIV-1 isolates by IF using a panel of anti-gag monoclonal antibodies and a panel of anti-HIV human sera (a)
Initially hybridomas were selected by both capture ELISA and by IF using infected and uninfected cells. Hybridomas that reacted with cell material (uninfected cells) were thus excluded at the outset. Repeated testing of reactive hybridoma SNF reduced the yield from 130 to 41 ; of this group, 13 were eventually cloned (Table 1) . Among these were two clones (EB1A9 and 1E8G2) which were positive by IF even though they failed to react in the ELISA and a further clone, DF9C3, which was reactive in the ELISA but negative in IF. Generally IF is considered to be less sensitive for detection of antibody than ELISA. Thus the failure to detect DF9C3 by IF could have been explained by a reduced sensitivity in the IF testing. However, it could also have been been due to an acetone-sensitive gag epitope. It is difficult to explain the results obtained with EB1A9 and 1E8G2. It may be that the conformation of the antigen used both for immunization and in the capture ELISA, the fl-propiolactone-treated CEM/CBL-1, was altered in some way in comparison to the antigens detected by IF in virus and cell preparations that were acetone-fixed. We hoped that selection of hybridomas reactive in either or both assays might broaden the specificities recognized and increase the chances of obtaining monoclonal antibodies which would recognize isolate-specific virus epitopes.
Analysis by Western blotting of SNF allowed the specificities of antibodies to be characterized prior to propagation in mice. Seven of the selected panel recognized HIV viral products p55 and p24, three recognized p55 and p18 and another three recognized p18 alone. p55, coded by the gag gene, is now considered to be the precursor protein to p18, p24 and p13 (Robey et al., 1985) and these proteins are cleaved from the p55 by the action of a virus-encoded protease. In this instance, a dual specificity for p55 and p24 or p55 and p18 is possible for a monoclonal antibody, though the epitopes that the antibodies recognized on p24 must also be present on the precursor protein for this to be true. The same probably applies to those antibodies which reacted with p 18 and p55. Antibodies reacting with pl 8 alone must recognize a unique epitope probably representing a post-cleavage or cryptic epitope unmasked by conformational changes following cleavage of the p55 polypeptide. Veronese et al. (1985) raised four monoclonal antibodies with HIV p24 specificities and Chassagne et al. (1986) raised a single antibody with p55, p40 and p18 reactivities; the p40 was considered to be another cleavage product of p55. Thus the 13 monoclonal antibodies described in this study are directed against three of the four viral products to which monoclonal antibodies have already been raised. However, previous studies have not attempted to examine the epitope specificity of the monoclonal antibodies either by competition analysis or by determining their reactivity to a wide range of HIV isolates.
Cross competition results with EH 12E 1 and CD 12B4 suggested that these recognized closely related though discrete epitopes on the p24 part of p55. The group of clones recognizing p55 and p18 or p18 alone appeared to cross-compete suggesting that a single antigenic site was being recognized. However, many of these clones also inhibited and were inhibited by 3D3 (p55/p24) implying that 3D3 possesses the broadest reactivity.
The failure of EB1A9 and 1E8G2 to bind to the solid phase antigen was predictable since they failed to bind in the capture ELISA (Table 1) . 1D8F6 appeared to lack accessible tyrosine residues for iodination. Part of the cross-inhibition caused by clone 9G5 in the competition assays may have been due to steric hindrance resulting from the binding of an IgM antibody. Originally, it had been hoped to develop solid-phase sandwich assays for use in characterizing gag proteins from various isolates. However, problems with four of the clones in this type of radioimmunoassay format led to the use of IF for examining the expression of various epitopes on different isolates of HIV (Table 3) . DF9C3 was the only clone selected which failed to detect CBL-I by fluorescence and also failed to detect viral antigens in any of the other isolates.
In the nine HIV isolates, expression of the virus was detected by at least three of the four polyclonal anti-HIV sera. Thus having established that the virus was expressed at similar levels, comparison of the monoclonal antibody IF results was possible. The panel of 12 IF-positive antibodies had no difficulty in detecting expression in the CBL-1, IIIB and Ma2 isolates, suggesting a similarity of gag epitopes in these isolates. This compares favourably with sequencing data available for CBL-1 and IIIB (P. Highfield, personal communication). Ma2 was isolated from a British patient after blood-product transmission (Webster et al., 1986) . Another isolate, ARV-2, from the U.S.A., was not detected by CD12B4 implying that it lacks this particular epitope (Table 2 ). This epitope was also lacking in the Haitian isolate RF. However the most notable differences in epitope expression were seen in the African isolates U455a, RUT and Z129. This supports the sequencing data variations in isolates from Africa (Benn et al., 1985; Alizon et al., 1986) .
Even though the technique of IF is subjective, using strict criteria i.e. an IF-positive result is only scored when the level of fluoresence with monoclonal antibodies is similar to that seen with polyclonal sera, the technique should be very specific because it uses well defined monoclonal antibodies and should be moderately sensitive to changes in gag products from different HIV isolates.
Genetic variations in HIV are known to occur , but whether these changes are manifest at a cellular level in the gag products is unclear. Also, env products, particularly gpl20, have been demonstrated to be genetically polymorphic, as reflected by their variable amino acid sequences (Hahn et al., 1985 ; Alizon et al., 1986; Coffin, 1986; Starcich et al., 1986) and this may be an important consideration in vaccine development, though human sera from British and Ugandan seropositive subjects cross neutralized all the HIV isolates used in this study .
We hope that this panel of anti-gag monoclonal antibodies will reveal more specifically any variations in the gag proteins present between different isolates at the cellular level. We also expect that anti-gag monoclonal antibodies will be useful in immunopathological studies as reagents for detecting specific proteins and in the development of diagnostic immunoassays.
